Table 4.

PK of tegaserod in IBS-C patients.

Treatment (BID)	Subjects	Pharmacokinetic Parameters (mean ± SD, median for tmax)
		Cmax,ss (ng/mL)	tmax,ss (h)	AUCτ (ng*h/mL)
6 mg tablets	C-IBS patients*	1.7 ± 0.7	1.0	5.7 ± 2.5
	D-IBS patients*	1.9 ± 1.4	1.0	4.8 ± 2.4
	Healthy volunteers§	2.7 ± 1.2	0.8	8.9 ± 4.2

*Data are referred to a study involving 54 patients for C-IBS or 32 patients for D-IBS [122]; § Data are referred to a study involving 18 subjects (11 male and 7 female) [121].